Lipocine (LPCN) EPS (Weighted Average and Diluted) (2016 - 2025)
Historic EPS (Weighted Average and Diluted) for Lipocine (LPCN) over the last 13 years, with Q3 2025 value amounting to -$0.59.
- Lipocine's EPS (Weighted Average and Diluted) fell 3409.09% to -$0.59 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.79, marking a year-over-year decrease of 13552.63%. This contributed to the annual value of -$0.0 for FY2024, which is 9994.82% up from last year.
- Per Lipocine's latest filing, its EPS (Weighted Average and Diluted) stood at -$0.59 for Q3 2025, which was down 3409.09% from -$0.41 recorded in Q2 2025.
- Lipocine's EPS (Weighted Average and Diluted)'s 5-year high stood at $0.66 during Q1 2024, with a 5-year trough of -$1.27 in Q3 2023.
- In the last 5 years, Lipocine's EPS (Weighted Average and Diluted) had a median value of -$0.42 in 2023 and averaged -$0.32.
- As far as peak fluctuations go, Lipocine's EPS (Weighted Average and Diluted) skyrocketed by 35000.0% in 2021, and later tumbled by 180000.0% in 2023.
- Lipocine's EPS (Weighted Average and Diluted) (Quarter) stood at $0.15 in 2021, then tumbled by 386.67% to -$0.43 in 2022, then increased by 2.33% to -$0.42 in 2023, then soared by 178.09% to $0.33 in 2024, then plummeted by 279.88% to -$0.59 in 2025.
- Its EPS (Weighted Average and Diluted) stands at -$0.59 for Q3 2025, versus -$0.41 for Q2 2025 and -$0.35 for Q1 2025.